Spyre Therapeutics Inc. (SYRE)
SYRE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/0001636282-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SYRE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001636282 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$155.2M |
| Operating income | -$209.6M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $85.7M |
| Total assets | $777.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $82.7M cash; operating cash flow -$62.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 94,969,184 (2026-10-27); 77,592,130 a year earlier; 4,048,927 three years earlier. | Cover page 2026-10-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-10-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $436.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$96.1M | -$77.5M | $82.7M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | Not filed | -$36.2M | -$69.9M | $162.0M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q1 2026 2026-03-31 | Not filed | -$69.0M | -$57.4M | $97.2M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q4 2025 2025-12-31 | Not filed | -$62.5M | -$44.6M | $85.7M | No debt tags | $0 | 10-K 2026-02-19 |
| Q3 2025 2025-09-30 | Not filed | -$11.2M | -$37.1M | $64.9M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | Not filed | -$36.7M | -$46.6M | $81.7M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q1 2025 2025-03-31 | Not filed | -$44.8M | -$41.0M | $48.5M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q4 2024 2024-12-31 | $0 | -$56.3M | -$37.2M | $89.4M | No debt tags | $0 | 10-K 2026-02-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-06 |
| Latest annual report | 10-K | 2026-02-19 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 823 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.1% |
| 1 month | +29.3% |
| 3 months | +2.1% |
| Year to date | +217.5% |
| 1 year | +359.6% |
| From 52-week high | -4.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. Common Stock | $11.82 | -16.47% | $9.5B |
| TGTX | TG Therapeutics Inc. | $62.76 | -2.71% | $9.5B |
| MDGL | Madrigal Pharmaceuticals Inc. | $423.96 | -0.80% | $9.8B |
| PRAX | Praxis Precision Medicines Inc. | $310.27 | -5.44% | $8.7B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
| BMRN | BioMarin Pharmaceutical Inc. | $57.99 | +1.33% | $11.2B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier